

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-49 (Cancelled)

50. **(Previously Presented)** A method for treating a thrombotic condition in a mammal, said method comprising administering to said mammal a pharmacologically acceptable dose of a low molecular weight heparin (LMWH) compound having a molecular weight of about 5,000 Daltons to about 9,000 Daltons.

51. **(Previously Presented)** The method in accordance with claim 50, wherein said LMWH compound (1) inhibits fibrin-bound thrombin and fluid-phase thrombin by catalyzing antithrombin, and (2) thrombin generation by catalyzing factor Xa inactivation by antithrombin.

52. **(Previously Presented)** The method in accordance with claim 50, wherein said LMWH compound has an anti-factor IIa activity of about 40 U/mg to about 100 U/mg, and an anti-factor Xa activity of about 90 U/mg to about 150 U/mg.

53. **(Previously Presented)** The method in accordance with claim 52, wherein said LMWH compound has an anti-factor Ha activity of about 60 U/mg to about 75 U/mg, and an anti-factor Xa

activity of about 100 U/mg to about 125 U/mg.

54. **(Previously Presented)** The method in accordance with claim 53, wherein said LMWH compound has an anti-factor IIa activity of about 65 U/mg, and an anti-factor Xa activity of about 115 U/mg.

55. **(Previously Presented)** The method in accordance with claim 50, wherein said LMWH compound has a molecular weight of about 5,400 Daltons to about 8,000 Daltons.

56. **(Previously Presented)** The method in accordance with claim 50, wherein said LMWH, wherein said MLMWH compound has a molecular weight of about 5,800 Daltons to about 7,000 Daltons.

57. **(Previously Presented)** The method in accordance with claim 50, wherein said LMWH compound has a molecular weight of about 6,000 Daltons.

58. **(Previously Presented)** The method in accordance with claim 50, wherein said thrombotic condition is arterial thrombosis.

59. **(Previously Presented)** The method in accordance with claim 50, wherein said thrombotic

condition is coronary artery thrombosis.

60. **(Previously Presented)** The method in accordance with claim 50, wherein said thrombotic condition is venous thrombosis.

61. **(Previously Presented)** The method in accordance with claim 50, wherein said thrombotic condition is pulmonary embolism.

62. **(Previously Presented)** A method for inhibiting thrombus formation in a patient, said method comprising the step of administering to the patient a pharmacologically acceptable dose of a low molecular weight heparin (LMWH) compound having a molecular weight of about 5,000 Daltons to about 9,000 Daltons.